You are here

CDC Teams Up With Dialysis Groups to Reduce Infections

First stakeholder meeting to be held this month

The Centers for Disease Control and Prevention (CDC) has joined a coalition of kidney and dialysis organizations to reduce the number of bloodstream infections in dialysis patients. Each year, approximately 37,000 people develop potentially deadly bloodstream infections related to their dialysis treatment.

For several years, facilities that have followed CDC recommendations have been successful in reducing bloodstream infections in dialysis patients, according to the agency. The new initiative, called the Making Dialysis Safer for Patients Coalition, is a partnership of health care-related organizations, patient advocacy groups, industry partners, and other public health partners that span the dialysis spectrum. The coalition aims to prevent bloodstream infections in hemodialysis patients, and to increase the use and visibility of CDC evidence-based practices. The CDC, together with the CDC Foundation, will host the coalition’s first stakeholder meeting this month.

“Making evidence-based safety steps a routine part of patient care is a proven strategy to keep dialysis patients safe from bloodstream infections,” said CDC Director Tom Frieden, MD, MPH. “We appreciate the new coalition of kidney and dialysis organizations stepping forward to protect the health of dialysis patients.”

The CDC is providing facilities with a package of resources that includes checklists, audit tools, how-to videos, continuing education training, and patient resources.

Coalition partners have committed to educating their membership and staff; raising awareness among patients and health care providers about the importance of infection prevention; helping to implement CDC recommendations in dialysis facilities; and sharing best practices. The coalition is also working with dialysis delivery organizations to accelerate the implementation of CDC recommendations. Initial coalition partners include the National Kidney Foundation, the American Society of Nephrology, and the Centers for Medicare and Medicaid Services.

Sources: CDC; September 27, 2016; and Dialysis Coalition; September 26, 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Synergistic Effects Seen When Combined With Cisplatin in Mice